Ian Jackson
Pulmonary Disease · Omaha, NENPI 1326602459
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AstraZeneca at 34.4% of the total. 2025 is the largest year on record at $1,359, more than ten times the $31 reported in 2022. That places this record below the midpoint for pulmonary disease clinicians in NE, where the typical reported total is $2,614.
Across 79 payments — averaging $28.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$760
- United Therapeutics Corporation$549
- Merck$178
- Insmed, Inc.$118
- Jazz Pharmaceuticals Inc.$106
- Amgen$73
- plus $430 from 14 others
What the payments were for
- Food & beverage$2,19499%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 24 | $760 |
| United Therapeutics Corporation | 9 | $549 |
| Merck | 7 | $178 |
| Insmed, Inc. | 6 | $118 |
| Jazz Pharmaceuticals Inc. | 6 | $106 |
| Amgen | 4 | $73 |
| Boehringer Ingelheim | 3 | $61 |
| GSK | 3 | $47 |
| Electromed, Inc. | 3 | $42 |
| Sanofi | 2 | $39 |
| Viatris Specialty LLC | 2 | $33 |
| Abiomed | 1 | $31 |
| Bayer | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Harmony Biosciences LLC | 1 | $24 |
| Liquidia Technologies, Inc. | 1 | $23 |
| Getinge USA Sales, LLC | 1 | $21 |
| Baxter Healthcare | 1 | $21 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $19 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,213 in reported general payments places this provider in the 45th percentile of 81 pulmonary disease providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $26,647 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $6,019 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $288 |
| Montelukast Sodium | 13 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $47 | $26,64741 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Omaha
- Stephen RennardOmaha$50K
- Douglas MooreOmaha$40K
- Adam WellsOmaha$26K
- Zachary DepewOmaha$26K
- Michael SanleyOmaha$17K
- Adam HighleyOmaha$15K
- Carolina LandeenOmaha$14K
- Patrick MeyersOmaha$12K
- John DickinsonOmaha$8K
- Palvannanathan GanesanOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.